CliffBio
small molecule

AYVAKIT

AVAPRITINIB

Loss of exclusivityApril 2040latest FDA-listed patent expiry
CompanyBlueprint Medicines →See this company's full patent-cliff portfolio

Drug detail

Brand nameAYVAKIT
Active ingredientAVAPRITINIB
Strength50MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 2021
Marketing statusRX

Listed patents

PatentExpiresType
11999744April 2040use U-3168
11964980April 2040substance, product
9200002October 2034substance, product
9944651October 2034substance, product
9994575October 2034substance, product

Regulatory exclusivity

CodeExpires
ODE-434May 2030
ODE-356June 2028
ODE-366January 2027

More from Blueprint Medicines

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AYVAKIT patent cliff — loss of exclusivity April 2040 | CliffBio